Oreopoulos D G, Husdan H, Harrison J, Meema H E, McNeill K G, Murray T M, Ogilvie R, Rapoport A
Can Med Assoc J. 1977 Apr 23;116(8):851-5.
Metabolic balance and calcium kinetic studies were performed in four patients with Paget's disease before treatment with salmon calcitonin and during the early and late stages of the treatment, which lasted 9 to 19 months, A significant decrease in bone turnover and 24-hour urine hydroxyproline and serum alkaline phosphatase values was observed in all patients. In contrast, the calcium, phosphorus and magnesium balances did not change significantly. In agreement with this, the partial body calcium, measured by in vivo neutron activation analysis, did not change. Intestinal calcium absorption increased initially, but returned to baseline levels 9 to 19 months after the study began. During the initial period there was a small, significant, but transient decrease in tubular reabsorption of phosphorus; this was accompanied by a significant decrease in serum phosphorus values--probably a direct effect of calcitonin rather than evidence of secondary hyperparathyroidism. Administration of salmon calcitonin to patients with Paget's disease decreases bone turnover without affecting calcium and phosphorus balances.
在4例佩吉特病患者中,于鲑鱼降钙素治疗前以及治疗的早期和晚期(治疗持续9至19个月)进行了代谢平衡和钙动力学研究。所有患者均观察到骨转换、24小时尿羟脯氨酸和血清碱性磷酸酶值显著降低。相比之下,钙、磷和镁平衡无显著变化。与此一致,通过体内中子活化分析测量的全身钙含量未改变。肠道钙吸收最初增加,但在研究开始9至19个月后恢复至基线水平。在最初阶段,磷的肾小管重吸收有小幅、显著但短暂的降低;这伴随着血清磷值的显著降低——这可能是降钙素的直接作用,而非继发性甲状旁腺功能亢进的证据。对佩吉特病患者给予鲑鱼降钙素可降低骨转换,而不影响钙和磷平衡。